ZYME Stock — Zymeworks Inc.: Cash, EV, Pipeline

Share price

$26.57

Market cap

$1,885.4M

Cash

$270.7M

Enterprise value

$1,614.7M

Balance sheet

Cash	$270.7M
Debt	$0.0M
Net cash	$270.7M
Enterprise value	$1,614.7M
Basic shares	71.4M shares
Fully diluted shares	88.7M shares
Fully diluted market cap	$2,357.8M
Cash per share	$3.79

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ZYME daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	ZW191	Phase 1	Advanced Solid Tumors	—
Jul 13 - Aug 24	Futibatinib	Phase 3	Biliary Tract Neoplasms	—
Oct 13 - Nov 24	ZW251	Phase 1	Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer; Germ Cell Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

zanidatamab

Approved · Active Modality: bispecific HER2-directed antibody

Aliases Ziihera

Target HER2

Partnerships Jazz Pharmaceuticals (license agreement; retains 70% of royalties on annual net sales under the Royalty Pharma financing after a 30% interest in Ziihera royalties was sold on March 2, 2026); BeOne Medicines (license agreement relating to Ziihera)

Indications

HER2-positive biliary tract cancer (previously treated, unresectable or metastatic) (Approved)
HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (first-line, in combination with chemotherapy) (Approved)

Status note Approved product commercialized by partners; Zymeworks recognizes royalty revenue in the period in which the commercial partner sells the product. The 10-Q names no internal clinical pipeline candidates with disclosed stages, so only this approved partnered asset is included.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ZW191
Lead indication	Advanced Solid Tumors
Lead phase	Phase 1
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06555744	Phase 1	Active, not recruiting	Sponsor	ZYME	—	Advanced Solid Tumors	—
NCT07164313	Phase 1	Recruiting	Sponsor	ZYME	—	Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer; Germ Cell Tumor	—
NCT05615818	Phase 3	Recruiting	Collaborator	UNICANCER	—	Biliary Tract Neoplasms	—
NCT05035836	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Breast Cancer; HER2-positive	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Zymeworks BC Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ZYME — Zymeworks Inc.